Immunotherapy startup shutters Boston research site, lays off 17


An immunotherapy startup that pulled off a $133 million IPO last year is shuttering its Boston research operations and laying off about 40% of its workforce.

Previous Families before profits: How nonprofit managed care benefits the whole health of Georgians
Next Bouldin Acres 2.0: Co-owner of popular South Lamar hangout talks North Austin expansion plans